CICLOPIROX- ciclopirox shampoo
Fougera Pharmaceuticals Inc.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CICLOPIROX SHAMPOO safely and effectively. See full prescribing information for CICLOPIROX SHAMPOO.
CICLOPIROX SHAMPOO 1% for topical use
Initial U.S. Approval: 1982
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
To report SUSPECTED ADVERSE REACTIONS, contact Fougera Pharmaceuticals Inc. at 1-800-645-9833 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
FULL PRESCRIBING INFORMATION: CONTENTS*
Ciclopirox Shampoo is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.
Ciclopirox Shampoo is not for ophthalmic, oral, or intravaginal use.
Wet hair and apply approximately 1 teaspoon (5 mL) of Ciclopirox Shampoo to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.
If a patient with seborrheic dermatitis shows no clinical improvement after 4 weeks of treatment with Ciclopirox Shampoo, the diagnosis should be reviewed.
Ciclopirox shampoo contains 1% ciclopirox.
Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo contains 10 mg ciclopirox in a colorless and translucent shampoo base.
If a reaction suggesting sensitivity or irritation occurs with the use of Ciclopirox Shampoo, treatment should be discontinued and appropriate therapy instituted.
Contact of Ciclopirox Shampoo with the eyes should be avoided. If contact occurs, rinse thoroughly with water.
In patients with lighter hair color, hair discoloration has been reported.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In 626 subjects treated with Ciclopirox Shampoo twice weekly in the two pivotal clinical trials, the most frequent adverse events were increased itching in 1% of subjects, and application site reactions, such as burning, erythema, and itching, also in 1% of subjects.
The following adverse reactions have been identified during post approval use of Ciclopirox Shampoo: hair discoloration and abnormal hair texture, alopecia, irritation and rash. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Teratogenic Effects: Pregnancy Category B
There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox Shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively).
Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox Shampoo is administered to a nursing woman.
In clinical trials, the safety and tolerability of Ciclopirox Shampoo in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with Ciclopirox Shampoo, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.
Ciclopirox Shampoo 1% contains the synthetic antifungal agent, ciclopirox for topical use.
Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo contains 10 mg ciclopirox in a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water USP, sodium chloride USP, and sodium laureth sulfate.
Ciclopirox Shampoo is a colorless, translucent solution. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, with the empirical formula C12H17NO2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:
Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.
In a study in patients with seborrheic dermatitis of the scalp, application of 5 mL ciclopirox shampoo 1% twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/mL. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.
A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mg/m2/day). No increase in drug related neoplasms was noted when compared to control.
The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.
A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).
In two randomized, double-blind clinical trials, subjects 16 years and older with seborrheic dermatitis of the scalp applied Ciclopirox Shampoo or its vehicle twice weekly for 4 weeks. Subjects who were immunocompromised, those with psoriasis or atopic dermatitis, women of childbearing potential not using adequate contraception, and pregnant or lactating women were excluded from the clinical trials. An evaluation of the overall status of the seborrheic dermatitis, the presence and severity of erythema or inflammation, and scaling, was made at week 4, using a scale of 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = pronounced, and 5 = severe. Effective treatment was defined as achieving a score of 0 (or a score of 1 if the baseline score was ≥ 3) simultaneously for status of the seborrheic dermatitis, erythema or inflammation, and scaling at Week 4. Ciclopirox shampoo was shown to be statistically significantly more effective than vehicle in both trials. Efficacy results for the two trials are presented in Table 1 below.
Efficacy for African American subjects was not demonstrated, although only 53 African American subjects were enrolled in the two pivotal trials.
Ciclopirox Shampoo 1% is colorless and translucent, and supplied in 120 mL plastic bottles (NDC 0168-0522-04).
Discard unused product after initial treatment duration.
See FDA-approved patient labeling (Patient Information)
The patient should be instructed to:
Important: For use on the scalp only. Do not get Ciclopirox Shampoo in your eyes, mouth, or vagina.
What is Ciclopirox Shampoo?
Ciclopirox Shampoo is a prescription medicine used on the scalp to treat adults with a skin condition called seborrheic dermatitis.
It is not known if Ciclopirox Shampoo is safe and effective in children under 16 years of age.
What should I tell my doctor before using Ciclopirox Shampoo?
Before using Ciclopirox Shampoo, tell your doctor if you:
How should I use Ciclopirox Shampoo?
How should I apply Ciclopirox Shampoo?
What are the possible side effects of Ciclopirox Shampoo?
The most common side effects of Ciclopirox Shampoo include: itching, burning, and redness of the scalp. Tell your doctor if you get any of these symptoms and they become worse or do not go away, or if you get blistering, swelling, or oozing in your scalp.
These are not all the possible side effects of Ciclopirox Shampoo. For more information, ask your doctor.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Ciclopirox Shampoo?
Keep Ciclopirox Shampoo and all medicines out of the reach of children.
General information about Ciclopirox Shampoo
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Ciclopirox Shampoo for a condition for which it was not prescribed. Do not give Ciclopirox Shampoo to other people, even if they have the same symptoms you have. It may harm them.
You can ask your pharmacist or doctor for information about Ciclopirox Shampoo that is written for health professionals.
For more information about Ciclopirox Shampoo, call 1-800-645-9833.
What are the ingredients in Ciclopirox Shampoo?
Active ingredient: ciclopirox
Inactive ingredients: disodium laureth sulfosuccinate, laureth-2, purified water USP, sodium chloride USP, and sodium laureth sulfate.
E. FOUGERA & CO.
A division of
Melville, New York 11747
Contract Pharmaceutical Limited,
Mississauga, Ontario L5N 6L6, CANADA
This Patient Information has been approved by the U.S. Food and Drug Administration.
Product of Italy
U.S. Patent 7,981,909; 8,277,490 and Patents Pending
PRINCIPAL DISPLAY PANEL - 120 mL Bottle Carton
FOR TOPICAL USE ONLY.
NOT FOR OPHTHALMIC, ORAL
OR INTRAVAGINAL USE.
KEEP OUT OF REACH OF CHILDREN.
PRINCIPAL DISPLAY PANEL - 120 mL Bottle Container
FOR TOPICAL USE ONLY.
KEEP OUT OF REACH OF CHILDREN.
|Labeler - Fougera Pharmaceuticals Inc. (043838424)|
|Contract Pharmaceuticals Limited Canada||248761249||MANUFACTURE(0168-0522)|